Following their breakout moment with Final Destination: Bloodlines, Zach Lipovsky and Adam B. Stein are eyeing to direct an animated Venom movie for Sony, Deadline can confirm. No word on the plot of ...

Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...

It’s normal to feel overwhelmed when you’re diagnosed with large B-cell lymphoma (LBCL) and for that feeling to continue as you start treatment. Though a lot of things are out of your control — how ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Scientists analyzing human and mouse pancreatic lymph nodes (PLNs) and spleens have identified a distinct subset of CD4 memory helper T cells associated with type 1 diabetes (T1D). Reported by ...

Sonrotoclax is a next-generation and potentially best-in-class investigational B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Studies in the lab and ...

GameSpot may get a commission from retail offers. Splinter Cell's dedicated fans have noticed that the new Netflix animated series, Splinter Cell: Deathwatch, has been featuring callbacks to the death ...

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

Ubisoft still isn’t giving us a new Splinter Cell game, but Sam Fisher fans are at least getting an animated TV adaptation very soon. At this week’s Anime NYC convention, Netflix revealed a new teaser ...

GameSpot may get a commission from retail offers. It's been 12 years since Splinter Cell's Sam Fisher suited up for action in a video game, but Tom Clancy's iconic hero is getting a comeback on ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...